EdiGene Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 140

Employees

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $61.1M

  • Investors
  • 19

EdiGene General Information

Description

Operator of a clinical-stage biotechnology company focused on leveraging cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies, enabling drug discovery companies to conduct high-throughput genome screening and detection of functional big data in biological contexts.

Contact Information

Website
www.edigene.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 2, 22 Science Park Road
  • Zhongguancun Life Science Park, Changping District
  • Beijing
  • China
+86 010
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Building 2, 22 Science Park Road
  • Zhongguancun Life Science Park, Changping District
  • Beijing
  • China
+86 010

EdiGene Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EdiGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B1) 21-Apr-2021 $61.1M Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B) 13-Oct-2020 Completed Pre-Clinical Trials
5. Early Stage VC 17-Sep-2019 Completed Pre-Clinical Trials
4. Early Stage VC 04-Feb-2019 Completed Pre-Clinical Trials
3. Early Stage VC 08-Aug-2018 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Oct-2016 Completed Pre-Clinical Trials
1. Angel (individual) 01-Dec-2015 Completed Startup
To view EdiGene’s complete valuation and funding history, request access »

EdiGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company focused on leveraging cutting-edge genome editing technologies to acc
Biotechnology
Beijing, China
140 As of 2021

Zug, Switzerland
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EdiGene Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Eloxx Pharmaceuticals Formerly VC-backed Watertown, MA
Editas Medicine Formerly VC-backed Cambridge, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Caribou Biosciences Formerly VC-backed Berkeley, CA
You’re viewing 5 of 16 competitors. Get the full list »

EdiGene Patents

  • 112

    Total Documents Applications and Grants

  • Total Patents Families

  • 32

    Granted

  • 44

    Pending

  • Expiring in next 12 mo

EdiGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240058387-A1 Culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of hscs and application thereof Pending 28-Dec-2020
CA-3197230-A1 Cell preparation, use of protein in characterizing hematopoietic stem cells, and method for determining hematopoietic stem cells Pending 03-Nov-2020
JP-2023547692-A Cell preparations, use of proteins to characterize hematopoietic stem cells, and methods for determining hematopoietic stem cells Inactive 03-Nov-2020
EP-4242297-A1 Cell preparation, use of protein in characterizing hematopoietic stem cells, and method for determining hematopoietic stem cells Inactive 03-Nov-2020
US-20240011988-A1 Cell preparation, use of protein in characterizing hematopoietic stem cells, and method for determining hematopoietic stem cells Pending 03-Nov-2020 G01N33/56966
To view EdiGene’s complete patent history, request access »

EdiGene Executive Team (6)

Name Title Board Seat
Yajun Si Chief Operating Officer & Co-Founder
Pengfei Yuan Ph.D Chief Technology Officer & Head of Research System (Central)
Wensheng Wei Ph.D Scientific Founder
You’re viewing 3 of 6 executive team members. Get the full list »

EdiGene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EdiGene Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioTrack Capital Venture Capital Minority
jVEN Capital Venture Capital Minority
Kunlun Technology Corporation Minority
Loyal Valley Capital Growth/Expansion Minority
Sherpa Healthcare Partners Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

EdiGene FAQs

  • When was EdiGene founded?

    EdiGene was founded in 2015.

  • Who is the founder of EdiGene?

    Yajun Si and Wensheng Wei Ph.D are the founders of EdiGene.

  • Where is EdiGene headquartered?

    EdiGene is headquartered in Beijing, China.

  • What is the size of EdiGene?

    EdiGene has 140 total employees.

  • What industry is EdiGene in?

    EdiGene’s primary industry is Biotechnology.

  • Is EdiGene a private or public company?

    EdiGene is a Private company.

  • What is the current valuation of EdiGene?

    The current valuation of EdiGene is .

  • What is EdiGene’s current revenue?

    The current revenue for EdiGene is .

  • How much funding has EdiGene raised over time?

    EdiGene has raised $164M.

  • Who are EdiGene’s investors?

    BioTrack Capital, jVEN Capital, Kunlun Technology, Loyal Valley Capital, and Sherpa Healthcare Partners are 5 of 19 investors who have invested in EdiGene.

  • Who are EdiGene’s competitors?

    CRISPR Therapeutics, Eloxx Pharmaceuticals, Editas Medicine, Intellia Therapeutics, and Caribou Biosciences are some of the 16 competitors of EdiGene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »